Overweight study: Eloralintide
Official title A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ClinicalTrials.gov ID: NCT07282600
What this study is testing
What is Eloralintide?
An investigational subcutaneous injectable medicine being studied for weight reduction in people who are overweight or have obesity and type 2 diabetes.
Also referred to as LY3841136.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out whether eloralintide safely reduces body weight compared with a placebo in people who are overweight or obese and have type 2 diabetes.
- Who it's for
- Adults who have overweight or obesity together with type 2 diabetes.
- What's involved
- Participants will be randomly given either eloralintide or a placebo and will attend regular clinic visits for dosing, weight checks, and safety tests.
- Time commitment
- The trial lasts about 75 weeks and includes multiple scheduled visits throughout that period.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Have type 2 diabetes
- Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
- Have a BMI ≥ 27 kg/m2
- Have a stable body weight (\<5% body weight change) for 90 days prior to screening
You likely can't join if
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was...
- Have type 1 diabetes
- amylin analogs
- glucagon-like peptide-1 (GLP-1) receptor agonists
- glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or
See the full eligibility criteria
- Have type 2 diabetes
- Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
- Have a BMI ≥ 27 kg/m2
- Have a stable body weight (\<5% body weight change) for 90 days prior to screening
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Have type 1 diabetes
- amylin analogs
- glucagon-like peptide-1 (GLP-1) receptor agonists
- glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or
- insulin
- heart attack
- stroke
- coronary artery revascularization
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
- Have taken medications or alternative remedies intended for weight loss within 90 days of screening
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Cullman, Alabama, United States
- Tucson, Arizona, United States
- Canoga Park, California, United States
- Escondido, California, United States
- Greenbrae, California, United States
- Long Beach, California, United States
- Los Alamitos, California, United States
- Los Angeles, California, United States
- Santa Clarita, California, United States
- Spring Valley, California, United States
- Walnut Creek, California, United States
- Aurora, Colorado, United States
- Bridgeport, Connecticut, United States
- Hamden, Connecticut, United States
- Daytona Beach, Florida, United States
- Delray Beach, Florida, United States
- Fleming Island, Florida, United States
- Inverness, Florida, United States
- Jacksonville, Florida, United States
+ 90 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Cullman, Alabama, United States; Tucson, Arizona, United States; Canoga Park, California, United States; Escondido, California, United States; Greenbrae, California, United States and 104 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.